Wave Life Sciences Ltd. (NASDAQ: WVE) closed the day trading at $6.17 up 2.15% from the previous closing price of $6.04. In other words, the price has increased by $+0.13 from its previous closing price. On the day, 596426 shares were traded. WVE stock price reached its highest trading level at $6.18 during the session, while it also had its lowest trading level at $5.89.
Ratios:
For a better understanding of WVE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on December 19, 2023, Upgraded its rating to Outperform and sets its target price to $12 from $5 previously.
On July 05, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.
Jefferies Downgraded its Buy to Hold on May 24, 2023, whereas the target price for the stock was revised from $7 to $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’23 when RA CAPITAL MANAGEMENT, L.P. bought 1,000,000 shares for $5.00 per share. The transaction valued at 5,000,000 led to the insider holds 19,202,009 shares of the business.
GSK plc bought 3,300,000 shares of WVE for $16,500,000 on Dec 07 ’23. The 10% Owner now owns 13,983,761 shares after completing the transaction at $5.00 per share. On Aug 23 ’23, another insider, Moran Kyle, who serves as the Chief Financial Officer of the company, sold 37,062 shares for $4.75 each. As a result, the insider received 176,119 and left with 46,120 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 754.49M and an Enterprise Value of 586.26M. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.66 while its Price-to-Book (P/B) ratio in mrq is 18.55. Its current Enterprise Value per Revenue stands at 5.17 whereas that against EBITDA is -9.97.
Stock Price History:
Over the past 52 weeks, WVE has reached a high of $7.67, while it has fallen to a 52-week low of $3.15. The 50-Day Moving Average of the stock is 4.99, while the 200-Day Moving Average is calculated to be 4.90.
Shares Statistics:
Over the past 3-months, WVE traded about 930.36K shares per day on average, while over the past 10 days, WVE traded about 1.13M shares per day. A total of 119.16M shares are outstanding, with a floating share count of 95.63M. Insiders hold about 21.80% of the company’s shares, while institutions hold 74.64% stake in the company. Shares short for WVE as of Mar 15, 2024 were 3M with a Short Ratio of 3.22, compared to 2.51M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.45% and a Short% of Float of 4.43%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.04 and a low estimate of -$0.34, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.19 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.63 and -$1.32 for the fiscal current year, implying an average EPS of -$1.01. EPS for the following year is -$1.07, with 5 analysts recommending between -$0.87 and -$1.52.
Revenue Estimates
6 analysts predict $22.95M in revenue for the current quarter. It ranges from a high estimate of $39.67M to a low estimate of $10M. As of the current estimate, Wave Life Sciences Ltd.’s year-ago sales were $32.33M, an estimated decrease of -29.00% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $19.61M, an increase of 147.00% over than the figure of -$29.00% in the same quarter last year. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $10M.
A total of 6 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $100M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $76.38M. In the same quarter a year ago, actual revenue was $113.31M, down -32.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $52.83M in the next fiscal year. The high estimate is $98.36M and the low estimate is $6M. The average revenue growth estimate for next year is down -30.80% from the average revenue estimate for this year.
